

BIOCRYST PHARMACEUTICALS INC
 Form 4
 March 07, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Barnes Alane P

2. Issuer Name and Ticker or Trading Symbol
 BIOCRYST PHARMACEUTICALS INC [BCRX]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 4505 EMPEROR BLVD., SUITE 200
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 03/01/2014

____ Director
 Officer (give title below) _____ Other (specify below)
 VP, General Counsel & Corp Sec

DURHAM, NC 27703

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	03/01/2014		F		1,090 (1) \$ 11.69	D	
Common Stock	03/04/2014		M		12,500 \$ 4.73	D	
Common Stock	03/04/2014		M		6,156 \$ 6.68	D	
Common Stock	03/04/2014		M		2,518 \$ 4.15	D	
Common Stock	03/04/2014		M		10,000 \$ 1.42	D	

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Common Stock	03/04/2014	S	40,734	D	\$ 12.63 (2)	71,622	D
-----------------	------------	---	--------	---	--------------------	--------	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Emp. Stock Option (Right to Buy)	\$ 4.73	03/04/2014		M	12,500	03/01/2013	03/01/2022	Common Stock	12,500
Emp. Stock Option (Right to Buy)	\$ 6.68	03/04/2014		M	6,156	03/01/2011	03/01/2020	Common Stock	6,156
Emp. Stock Option (Right to Buy)	\$ 4.15	03/04/2014		M	2,518	03/01/2012	03/01/2021	Common Stock	2,518
Emp. Stock Option (Right to Buy)	\$ 1.42	03/04/2014		M	10,000	01/01/2014	01/01/2023	Common Stock	10,000

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

Director 10% Owner Officer

Other

Barnes Alane P
4505 EMPEROR BLVD.
SUITE 200
DURHAM, NC 27703

VP, General Counsel & Corp Sec

Signatures

/s/ Alane P. Barnes, by power of
attorney

03/07/2014

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares withheld by BioCryst Pharmaceuticals, Inc. upon the vesting of restricted stock to satisfy the reporting person's tax withholding obligations.
The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$12.44 to \$12.99. The
- (2) reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.